Pathogenesis, diagnosis, and management of cholangiocarcinoma

Gastroenterology

Volumn 145, Issue 6, 2013, Pages 1215-1229

  Ilyas, Sumera I ^a   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cancer Associated Fibroblasts; Distal Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma; Molecular Pathogenesis

Indexed keywords

CA 19-9 ANTIGEN; CISPLATIN; CYTOKERATIN 19; CYTOKERATIN 7; DNA; GEMCITABINE; ISOCITRATE DEHYDROGENASE; PROTEIN P53; TUMOR MARKER;

ALCOHOL CONSUMPTION; BILE DUCT CARCINOMA; BILE DUCT STONE; BILIARY TRACT SURGERY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CHRONIC INFLAMMATION; COMMON BILE DUCT STONE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIABETES MELLITUS; ENDOSCOPIC BIOPSY; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERITIS; FATTY LIVER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HEPATITIS; HEPATITIS B; HEPATITIS C; HEPATOJEJUNOSTOMY; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER TRANSPLANTATION; LYMPH NODE DISSECTION; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MICROENVIRONMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SMOKING; SOMATIC MUTATION; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR DIAGNOSIS; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

EID: 84888250929     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.10.013     Document Type: Review

References (150)

1. T.M. Welzel, K.A. McGlynn, and A.W. Hsing Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States J Natl Cancer Inst 98 2006 873 875
2. B. Blechacz, M. Komuta, and T. Roskams Clinical diagnosis and staging of cholangiocarcinoma Nat Rev Gastroenterol Hepatol 8 2011 512 522
3. M.L. Deoliveira, R.D. Schulick, and Y. Nimura New staging system and a registry for perihilar cholangiocarcinoma Hepatology 53 2011 1363 1371
4. M.L. DeOliveira, S.C. Cunningham, and J.L. Cameron Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution Ann Surg 245 2007 755 762
5. Blechacz BG, Gores, GJ. Tumors of the bile ducts, gallbladder, and ampulla. In: Feldman, ed. Sleisenger and Fordtran's gastrointestinal and liver disease. Volume 1. 9th ed. Philadelphia: Saunders, 2010:1171-1176.
6. S.A. Khan, B.R. Davidson, and R.D. Goldin Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update Gut 61 2012 1657 1669
7. J.E. Everhart, and C.E. Ruhl Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas Gastroenterology 136 2009 1134 1144
8. G.L. Tyson, and H.B. El-Serag Risk factors for cholangiocarcinoma Hepatology 54 2011 173 184
9. Y. Shaib, and H.B. El-Serag The epidemiology of cholangiocarcinoma Semin Liver Dis 24 2004 115 125
10. B. Sripa, and C. Pairojkul Cholangiocarcinoma: lessons from Thailand Curr Opin Gastroenterol 24 2008 349 356
11. S.A. Khan, S.D. Taylor-Robinson, M.B. Toledano, A. Beck, P. Elliott, and H.C. Thomas Changing international trends in mortality rates for liver, biliary and pancreatic tumours J Hepatol 37 2002 806 813
12. S.A. Khan, M.B. Toledano, and S.D. Taylor-Robinson Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma HPB (Oxford) 10 2008 77 82
13. K.A. McGlynn, R.E. Tarone, and H.B. El-Serag A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States Cancer Epidemiol Biomarkers Prev 15 2006 1198 1203
14. T. Patel Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States Hepatology 33 2001 1353 1357
15. T. Patel Worldwide trends in mortality from biliary tract malignancies BMC Cancer 2 2002 10
16. S.A. Khan, S. Emadossadaty, and N.G. Ladep Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol 56 2012 848 854
17. N. Razumilava, and G.J. Gores Classification, diagnosis, and management of cholangiocarcinoma Clin Gastroenterol Hepatol 11 2013 13 21 e1 quiz e3-e4
18. H.R. Shin, J.K. Oh, and M.K. Lim Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea J Korean Med Sci 25 2010 1011 1016
19. M.H. Huang, C.H. Chen, and C.M. Yen Relation of hepatolithiasis to helminthic infestation J Gastroenterol Hepatol 20 2005 141 146
20. B.H. Edil, J.L. Cameron, and S. Reddy Choledochal cyst disease in children and adults: a 30-year single-institution experience J Am Coll Surg 206 2008 1000 1005 discussion 1005-1008
21. J.Y. Mabrut, G. Bozio, and C. Hubert Management of congenital bile duct cysts Dig Surg 27 2010 12 18
22. I. Kato, and C. Kido Increased risk of death in thorotrast-exposed patients during the late follow-up period Jpn J Cancer Res 78 1987 1187 1192
23. T.Y. Lee, S.S. Lee, and S.W. Jung Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study Am J Gastroenterol 103 2008 1716 1720
24. Y.H. Shaib, H.B. El-Serag, and A.K. Nooka Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study Am J Gastroenterol 102 2007 1016 1021
25. H.T. Sorensen, S. Friis, and J.H. Olsen Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark Hepatology 28 1998 921 925
26. W.C. Palmer, and T. Patel Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma J Hepatol 57 2012 69 76
27. Y.H. Shaib, H.B. El-Serag, and J.A. Davila Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study Gastroenterology 128 2005 620 626
28. T.M. Welzel, B.I. Graubard, and H.B. El-Serag Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study Clin Gastroenterol Hepatol 5 2007 1221 1228
29. T.M. Welzel, L. Mellemkjaer, and G. Gloria Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study Int J Cancer 120 2007 638 641
30. Y. Nakanuma, Y. Sato, and K. Harada Pathological classification of intrahepatic cholangiocarcinoma based on a new concept World J Hepatol 2 2010 419 427
31. M. Komuta, B. Spee, and S. Vander Borght Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin Hepatology 47 2008 1544 1556
32. A. Tsuchiya, H. Kamimura, and Y. Tamura Hepatocellular carcinoma with progenitor cell features distinguishable by the hepatic stem/progenitor cell marker NCAM Cancer Lett 309 2011 95 103
33. V. Cardinale, G. Carpino, and L. Reid Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity World J Gastrointest Oncol 4 2012 94 102
34. M. Komuta, O. Govaere, and V. Vandecaveye Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes Hepatology 55 2012 1876 1888
35. B. Fan, Y. Malato, and D.F. Calvisi Cholangiocarcinomas can originate from hepatocytes in mice J Clin Invest 122 2012 2911 2915
36. S. Sekiya, and A. Suzuki Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes J Clin Invest 122 2012 3914 3918
37. A. Holczbauer, V.M. Factor, and J.B. Andersen Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types Gastroenterology 145 2013 221 231
38. M. Jaiswal, N.F. LaRusso, and L.J. Burgart Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism Cancer Res 60 2000 184 190
39. J. Park, L. Tadlock, and G.J. Gores Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line Hepatology 30 1999 1128 1133
40. S. Kobayashi, N.W. Werneburg, and S.F. Bronk Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells Gastroenterology 128 2005 2054 2065
41. M. Taniai, A. Grambihler, and H. Higuchi Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells Cancer Res 64 2004 3517 3524
42. H. Isomoto, S. Kobayashi, and N.W. Werneburg Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells Hepatology 42 2005 1329 1338
43. F. Meng, Y. Yamagiwa, and Y. Ueno Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes J Hepatol 44 2006 1055 1065
44. D. Sia, V. Tovar, and A. Moeini Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies Oncogene 32 2013 4861 4870
45. D. Sia, Y. Hoshida, and A. Villanueva Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes Gastroenterology 144 2013 829 840
46. H. Isomoto, J.L. Mott, and S. Kobayashi Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing Gastroenterology 132 2007 384 396
47. J.H. Yoon, G.Y. Gwak, and H.S. Lee Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells J Hepatol 41 2004 808 814
48. K. Kiguchi, S. Carbajal, and K. Chan Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma Cancer Res 61 2001 6971 6976
49. K. Matsumoto, and T. Nakamura Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions Int J Cancer 119 2006 477 483
50. K. Nishimura, M. Kitamura, and H. Miura Prostate stromal cell-derived hepatocyte growth factor induces invasion of prostate cancer cell line DU145 through tumor-stromal interaction Prostate 41 1999 145 153
51. T. Nakamura, K. Matsumoto, and A. Kiritoshi Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions Cancer Res 57 1997 3305 3313
52. P.M. Comoglio, S. Giordano, and L. Trusolino Drug development of MET inhibitors: targeting oncogene addiction and expedience Nat Rev Drug Discov 7 2008 504 516
53. G.H. Lai, S. Radaeva, and T. Nakamura Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated "intestinal-type" biliary cancer chemically induced in rat liver Hepatology 31 2000 1257 1265
54. M. Miyamoto, H. Ojima, and M. Iwasaki Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma Br J Cancer 105 2011 131 138
55. S. Radaeva, A. Ferreira-Gonzalez, and A.E. Sirica Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma Hepatology 29 1999 1453 1462
56. J.H. Yoon, H. Higuchi, and N.W. Werneburg Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line Gastroenterology 122 2002 985 993
57. J.H. Yoon, A.E. Canbay, and N.W. Werneburg Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis Hepatology 39 2004 732 738
58. R. Kuver Mechanisms of oxysterol-induced disease: insights from the biliary system Clin Lipidol 7 2012 537 548
59. S. Nachtergaele, L.K. Mydock, and K. Krishnan Oxysterols are allosteric activators of the oncoprotein Smoothened Nat Chem Biol 8 2012 211 220
60. C.D. Fingas, S.F. Bronk, and N.W. Werneburg Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells Hepatology 54 2011 2076 2088
61. J.B. Andersen, and S.S. Thorgeirsson Genetic profiling of intrahepatic cholangiocarcinoma Curr Opin Gastroenterol 28 2012 266 272
62. S.C. McKay, K. Unger, and S. Pericleous Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma HPB (Oxford) 13 2011 309 319
63. S.H. Koo, C.H. Ihm, and K.C. Kwon Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma Cancer Genet Cytogenet 130 2001 22 28
64. K.O. Uhm, Y.N. Park, and J.Y. Lee Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization Cancer Genet Cytogenet 157 2005 37 41
65. J.Y. Lee, Y.N. Park, and K.O. Uhm Genetic alterations in intrahepatic cholangiocarcinoma as revealed by degenerate oligonucleotide primed PCR-comparative genomic hybridization J Korean Med Sci 19 2004 682 687
66. N. Wong, L. Li, and K. Tsang Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma J Hepatol 37 2002 633 639
67. K. Homayounfar, B. Gunawan, and S. Cameron Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization Hum Pathol 40 2009 834 842
68. C.K. Ong, C. Subimerb, and C. Pairojkul Exome sequencing of liver fluke-associated cholangiocarcinoma Nat Genet 44 2012 690 693
69. R.F. Xu, J.P. Sun, and S.R. Zhang KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients Biomed Pharmacother 65 2011 22 26
70. K. Ohashi, Y. Nakajima, and H. Kanehiro Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology Gastroenterology 109 1995 1612 1617
71. J.B. Andersen, B. Spee, and B.R. Blechacz Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors Gastroenterology 142 2012 1021 1031 e15
72. M. Tada, M. Omata, and M. Ohto High incidence of ras gene mutation in intrahepatic cholangiocarcinoma Cancer 69 1992 1115 1118
73. S.A. Khan, H.C. Thomas, and M.B. Toledano p53 Mutations in human cholangiocarcinoma: a review Liver Int 25 2005 704 716
74. B.R. Kipp, J.S. Voss, and S.E. Kerr Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma Hum Pathol 43 2012 1552 1558
75. D.R. Borger, K.K. Tanabe, and K.C. Fan Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping Oncologist 17 2012 72 79
76. P. Wang, Q. Dong, and C. Zhang Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas Oncogene 32 2013 3091 3100
77. Z.J. Reitman, D.W. Parsons, and H. Yan IDH1 and IDH2: not your typical oncogenes Cancer Cell 17 2010 215 216
78. D. Rohle, J. Popovici-Muller, and N. Palaskas An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells Science 340 2013 626 630
79. F. Wang, J. Travins, and B. DeLaBarre Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation Science 340 2013 622 626
80. N. Oishi, M.R. Kumar, and S. Roessler Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma Hepatology 56 2012 1792 1803
81. L. Chen, H.X. Yan, and W. Yang The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma J Hepatol 50 2009 358 369
82. Y.M. Wu, F. Su, and S. Kalyana-Sundaram Identification of targetable FGFR gene fusions in diverse cancers Cancer Discov 3 2013 636 647
83. S. Yamanaka, A.V. Olaru, and F. An MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer Dig Liver Dis 44 2012 589 596
84. F. Meng, R. Henson, and M. Lang Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines Gastroenterology 130 2006 2113 2129
85. J.J. Hofmann, A.C. Zovein, and H. Koh Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndrome Development 137 2010 4061 4072
86. S. Zender, I. Nickeleit, and T. Wuestefeld A critical role for notch signaling in the formation of cholangiocellular carcinomas Cancer Cell 23 2013 784 795
87. A. Jinawath, Y. Akiyama, and B. Sripa Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells J Cancer Res Clin Oncol 133 2007 271 278
88. M. El Khatib, A. Kalnytska, and V. Palagani Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma Hepatology 57 2013 1035 1045
89. A.E. Sirica, M.H. Nathanson, and G.J. Gores Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M. and Lillian Stratton Basic Research Single-Topic Conference Hepatology 48 2008 2040 2046
90. S. Tanaka, K. Sugimachi, and T. Kameyama Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma Hepatology 37 2003 1122 1129
91. M.R. Junttila, and F.J. de Sauvage Influence of tumour micro-environment heterogeneity on therapeutic response Nature 501 2013 346 354
92. A.E. Sirica The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma Nat Rev Gastroenterol Hepatol 9 2012 44 54
93. R. Kalluri, and M. Zeisberg Fibroblasts in cancer Nat Rev Cancer 6 2006 392 401
94. J.A. Dranoff, and R.G. Wells Portal fibroblasts: underappreciated mediators of biliary fibrosis Hepatology 51 2010 1438 1444
95. H. Okabe, T. Beppu, and H. Hayashi Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma Ann Surg Oncol 16 2009 2555 2564
96. M. Quante, S.P. Tu, and H. Tomita Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth Cancer Cell 19 2011 257 272
97. T. Li, D. Li, and L. Cheng Epithelial-mesenchymal transition induced by hepatitis C virus core protein in cholangiocarcinoma Ann Surg Oncol 17 2010 1937 1944
98. Y. Sato, K. Harada, and K. Itatsu Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma Am J Pathol 177 2010 141 152
99. P.V. Korita, T. Wakai, and Y. Ajioka Aberrant expression of vimentin correlates with dedifferentiation and poor prognosis in patients with intrahepatic cholangiocarcinoma Anticancer Res 30 2010 2279 2285
100. M. Cadamuro, G. Nardo, and S. Indraccolo Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma Hepatology 58 2013 1042 1053
101. C.D. Fingas, J.C. Mertens, and N. Razumilava Targeting PDGFR-beta in cholangiocarcinoma Liver Int 32 2012 400 409
102. K. Utispan, P. Thuwajit, and Y. Abiko Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker Mol Cancer 9 2010 13
103. P. Baril, R. Gangeswaran, and P.C. Mahon Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway Oncogene 26 2007 2082 2094
104. A. Menakongka, and T. Suthiphongchai Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion World J Gastroenterol 16 2010 713 722
105. S. Ohira, M. Sasaki, and K. Harada Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma Am J Pathol 168 2006 1155 1168
106. K. Leelawat, S. Leelawat, and S. Narong Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion World J Gastroenterol 13 2007 1561 1568
107. T. Terada, Y. Okada, and Y. Nakanuma Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors Hepatology 23 1996 1341 1344
108. S. Prakobwong, P. Yongvanit, and Y. Hiraku Involvement of MMP-9 in peribiliary fibrosis and cholangiocarcinogenesis via Rac1-dependent DNA damage in a hamster model Int J Cancer 127 2010 2576 2587
109. S.J. Cohen, R.K. Alpaugh, and I. Palazzo Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma Pancreas 37 2008 154 158
110. J.C. Mertens, C.D. Fingas, and J.D. Christensen Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma Cancer Res 73 2013 897 907
111. K.S. Ko, J. Peng, and H. Yang Animal models of cholangiocarcinoma Curr Opin Gastroenterol 29 2013 312 318
112. G. Fava, L. Marucci, and S. Glaser gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway Cancer Res 65 2005 11437 11446
113. P. Pawar, L. Ma, and C.H. Byon Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin Clin Cancer Res 15 2009 1288 1296
114. T. Tang, J.W. Zheng, and B. Chen Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice Hepatobiliary Pancreat Dis Int 6 2007 303 307
115. J. Zhang, C. Han, and T. Wu MicroRNA-26a promotes cholangiocarcinoma growth by activating beta-catenin Gastroenterology 143 2012 246 256 e8
116. A.V. Olaru, G. Ghiaur, and S. Yamanaka MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint Hepatology 54 2011 2089 2098
117. K. Zhang, D. Chen, and X. Wang RNA interference targeting slug increases cholangiocarcinoma cell sensitivity to cisplatin via upregulating PUMA Int J Mol Sci 12 2011 385 400
118. S. Obchoei, S.M. Weakley, and S. Wongkham Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma Mol Cancer 10 2011 102
119. Y.J. Hou, L.W. Dong, and Y.X. Tan Inhibition of active autophagy induces apoptosis and increases chemosensitivity in cholangiocarcinoma Lab Invest 91 2011 1146 1157
120. X. Xu, S. Kobayashi, and W. Qiao Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice J Clin Invest 116 2006 1843 1852
121. P.A. Farazi, M. Zeisberg, and J. Glickman Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice Cancer Res 66 2006 6622 6627
122. H. Song, K.K. Mak, and L. Topol Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression Proc Natl Acad Sci U S A 107 2010 1431 1436
123. K.P. Lee, J.H. Lee, and T.S. Kim The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis Proc Natl Acad Sci U S A 107 2010 8248 8253
124. M.R. O'Dell, J.L. Huang, and C.L. Whitney-Miller Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma Cancer Res 72 2012 1557 1567
125. A.E. Sirica, Z. Zhang, and G.H. Lai A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines Hepatology 47 2008 1178 1190
126. D.J. Campbell, C.I. Dumur, and N.F. Lamour Novel organotypic culture model of cholangiocarcinoma progression Hepatol Res 42 2012 1119 1130
127. G. Fava, G. Alpini, and C. Rychlicki Leptin enhances cholangiocarcinoma cell growth Cancer Res 68 2008 6752 6761
128. H. Yang, T.W. Li, and J. Peng A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression Gastroenterology 141 2011 378 388 388 e1-e4
129. T. Plengsuriyakarn, V. Eursitthichai, and N. Labbunruang Ultrasonography as a tool for monitoring the development and progression of cholangiocarcinoma in Opisthorchis viverrini/dimethylnitrosamine-induced hamsters Asian Pac J Cancer Prev 13 2012 87 90
130. S. Yamasaki Intrahepatic cholangiocarcinoma: macroscopic type and stage classification J Hepatobiliary Pancreat Surg 10 2003 288 291
131. J. Rimola, A. Forner, and M. Reig Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma Hepatology 50 2009 791 798
132. V. Vilgrain Staging cholangiocarcinoma by imaging studies HPB (Oxford) 10 2008 106 109
133. B. Blechacz, and G.J. Gores Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment Hepatology 48 2008 308 321
134. A.H. Patel, D.M. Harnois, and G.G. Klee The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis Am J Gastroenterol 95 2000 204 207
135. G. Sapisochin, N. Fidelman, and J.P. Roberts Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma Liver Transpl 17 2011 934 942
136. I. Endo, M. Gonen, and A.C. Yopp Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection Ann Surg 248 2008 84 96
137. S.B. Choi, K.S. Kim, and J.Y. Choi The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival Ann Surg Oncol 16 2009 3048 3056
138. Y.Y. Li, H. Li, and P. Lv Prognostic value of cirrhosis for intrahepatic cholangiocarcinoma after surgical treatment J Gastrointest Surg 15 2011 608 613
139. L. Fabris, M. Cadamuro, and L. Moserle Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization Hepatology 54 2011 890 899
140. J.B. Kuhlmann, and H.E. Blum Locoregional therapy for cholangiocarcinoma Curr Opin Gastroenterol 29 2013 324 328
141. J. Valle, H. Wasan, and D.H. Palmer Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 2010 1273 1281
142. Y. Yamashita, M. Takahashi, and S. Kanazawa Hilar cholangiocarcinoma. An evaluation of subtypes with CT and angiography Acta Radiol 33 1992 351 355
143. J.K. Heimbach, W. Sanchez, and C.B. Rosen Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination HPB (Oxford) 13 2011 356 360
144. L.E. Moreno Luna, and B. Kipp Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures Gastroenterology 131 2006 1064 1072
145. E.G. Barr Fritcher, B.R. Kipp, and J.S. Voss Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma Am J Gastroenterol 106 2011 2023 2028
146. E.G. Barr Fritcher, J.S. Voss, and S.M. Jenkins Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy Cancer Cytopathol 2013 Epub ahead of print
147. D.M. Nagorney, and M.L. Kendrick Hepatic resection in the treatment of hilar cholangiocarcinoma Adv Surg 40 2006 159 171
148. S. Darwish Murad, W.R. Kim, and D.M. Harnois Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers Gastroenterology 143 2012 88 98 e3 quiz e14
149. J.C. Hong, C.M. Jones, and J.P. Duffy Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center Arch Surg 146 2011 683 689
150. D.M. Geynisman, and D.V. Catenacci Toward personalized treatment of advanced biliary tract cancers Discov Med 14 2012 41 57